BR0313212A - Aditivos de ácido de polialquileno glicol - Google Patents
Aditivos de ácido de polialquileno glicolInfo
- Publication number
- BR0313212A BR0313212A BR0313212-9A BR0313212A BR0313212A BR 0313212 A BR0313212 A BR 0313212A BR 0313212 A BR0313212 A BR 0313212A BR 0313212 A BR0313212 A BR 0313212A
- Authority
- BR
- Brazil
- Prior art keywords
- polyalkylene glycol
- acid additives
- glycol acid
- conjugates
- active
- Prior art date
Links
- 229920001515 polyalkylene glycol Polymers 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title abstract 2
- 239000000654 additive Substances 0.000 title abstract 2
- 229960000074 biopharmaceutical Drugs 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000002334 glycols Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 235000000346 sugar Nutrition 0.000 abstract 1
- 150000008163 sugars Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/337—Polymers modified by chemical after-treatment with organic compounds containing other elements
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39813702P | 2002-07-24 | 2002-07-24 | |
| PCT/EP2003/007736 WO2004012773A1 (en) | 2002-07-24 | 2003-07-16 | Polyalkylene glycol acid additives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0313212A true BR0313212A (pt) | 2005-06-28 |
Family
ID=31495718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0313212-9A BR0313212A (pt) | 2002-07-24 | 2003-07-16 | Aditivos de ácido de polialquileno glicol |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7193031B2 (https=) |
| EP (1) | EP1526872A1 (https=) |
| JP (2) | JP4451308B2 (https=) |
| KR (1) | KR100608415B1 (https=) |
| CN (1) | CN100337689C (https=) |
| AR (1) | AR040654A1 (https=) |
| AU (1) | AU2003258518B2 (https=) |
| BR (1) | BR0313212A (https=) |
| CA (1) | CA2492775C (https=) |
| MX (1) | MXPA05000796A (https=) |
| PL (1) | PL375265A1 (https=) |
| RU (1) | RU2318004C2 (https=) |
| WO (1) | WO2004012773A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| ES2348230T3 (es) * | 2002-06-07 | 2010-12-01 | Dyax Corp. | Prevención y reducción de la isquemia. |
| MXPA05000796A (es) * | 2002-07-24 | 2005-04-19 | Hoffmann La Roche | Aditivos de acidos polialquilenglicolicos. |
| AU2004268144A1 (en) * | 2003-08-29 | 2005-03-10 | Dyax Corp. | Modified protease inhibitors |
| US20050089515A1 (en) * | 2003-08-29 | 2005-04-28 | Dyax Corp. | Poly-pegylated protease inhibitors |
| KR101276422B1 (ko) | 2004-03-15 | 2013-06-19 | 넥타르 테라퓨틱스 | Ｈｉｖ 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트 |
| CA2567630A1 (en) * | 2004-05-17 | 2005-11-24 | Mcmaster University | Biological molecule-reactive hydrophilic silicone surface |
| CN101031323A (zh) | 2004-07-16 | 2007-09-05 | 尼克塔治疗亚拉巴马公司 | Gm－csf部分与聚合物的缀合物 |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| CA2619709C (en) * | 2005-08-26 | 2012-05-01 | Novo Nordisk A/S | A method of modifying a macromolecular system |
| ATE425204T1 (de) * | 2005-08-26 | 2009-03-15 | Novo Nordisk As | Verfahren zur modifizierung eines makromolekularen systems |
| US8133707B2 (en) * | 2006-01-17 | 2012-03-13 | Enzon Pharmaceuticals, Inc. | Methods of preparing activated polymers having alpha nitrogen groups |
| AR067536A1 (es) | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea |
| CL2008002053A1 (es) | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion. |
| US20090075887A1 (en) * | 2007-08-21 | 2009-03-19 | Genzyme Corporation | Treatment with Kallikrein Inhibitors |
| AU2009282413B2 (en) | 2008-08-11 | 2014-07-17 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
| US8637454B2 (en) | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| SMT201800552T1 (it) | 2010-01-06 | 2018-11-09 | Dyax Corp | Proteine che legano la callicreina plasmatica |
| US10040761B2 (en) * | 2010-06-25 | 2018-08-07 | Nof Corporation | Branched hetero polyethylene glycol and intermediate |
| WO2012088445A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| WO2012088422A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| KR102320178B1 (ko) | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| JP2015514718A (ja) * | 2012-04-03 | 2015-05-21 | サンガート， インコーポレイテッド | スクシンイミド活性化されたニトロキシル化合物およびタンパク質のニトロキシル化のためのその使用のための方法 |
| CN102816227A (zh) * | 2012-08-30 | 2012-12-12 | 深圳赛保尔生物药业有限公司 | 回收促红细胞生成素的方法 |
| JP6657070B2 (ja) | 2013-03-15 | 2020-03-04 | ウィリアム・シンドラーＷｉｌｌｉａｍ Ｓｃｈｉｎｄｌｅｒ | ポリアルキレンオキシド吉草酸ヘモグロビン接合体 |
| US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| EP3387018A1 (en) | 2015-12-11 | 2018-10-17 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| WO2020203583A1 (ja) * | 2019-03-29 | 2020-10-08 | 日油株式会社 | 末端カルボキシル基含有ポリエチレングリコールの製造方法および活性化ポリエチレングリコールの製造方法 |
| EP4090427A1 (en) | 2020-01-13 | 2022-11-23 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5849450B2 (ja) | 1975-07-09 | 1983-11-04 | 株式会社日立製作所 | スイリヨクシキカプセルユソウソウチノ ボウシクホウ |
| EP0206448B1 (en) * | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| JP2531661B2 (ja) | 1987-02-25 | 1996-09-04 | 味の素株式会社 | 酸素運搬剤 |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| ATE214940T1 (de) * | 1993-11-10 | 2002-04-15 | Enzon Inc | Verbesserte interferon-polymerkonjugate |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| RU2177950C2 (ru) * | 1996-10-25 | 2002-01-10 | Нексстар Фармасьютикалз, Инк. | Комплексы нуклеиновых кислот - лигандов сосудистого эндотелиального фактора роста (vegf) |
| IL144361A0 (en) | 1999-01-29 | 2002-05-23 | Hoffmann La Roche | Gcsf conjugates |
| CO5160259A1 (es) | 1999-03-02 | 2002-05-30 | Schering Corp | Interferon alfa pegilado en la terapia contra el hiv |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| DK1455839T3 (da) | 1999-10-08 | 2013-05-06 | Nektar Therapeutics | Heterobifunktioneller poly(ethylenglycol)-derivater og fremgangsmåder til fremstilling heraf |
| CA2394980C (en) * | 1999-12-22 | 2008-05-13 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
| US20020065397A1 (en) | 2000-10-12 | 2002-05-30 | Joseph Roberts | Protecting therapeutic compositions from host-mediated inactivation |
| EP1345628B1 (en) * | 2000-12-20 | 2011-04-13 | F. Hoffmann-La Roche AG | Conjugates of erythropoietin (epo) with polyethylene glycol (peg) |
| MXPA05000796A (es) * | 2002-07-24 | 2005-04-19 | Hoffmann La Roche | Aditivos de acidos polialquilenglicolicos. |
-
2003
- 2003-07-16 MX MXPA05000796A patent/MXPA05000796A/es active IP Right Grant
- 2003-07-16 AU AU2003258518A patent/AU2003258518B2/en not_active Ceased
- 2003-07-16 BR BR0313212-9A patent/BR0313212A/pt not_active Application Discontinuation
- 2003-07-16 WO PCT/EP2003/007736 patent/WO2004012773A1/en not_active Ceased
- 2003-07-16 JP JP2004525225A patent/JP4451308B2/ja not_active Expired - Fee Related
- 2003-07-16 CN CNB038175088A patent/CN100337689C/zh not_active Expired - Fee Related
- 2003-07-16 EP EP03766196A patent/EP1526872A1/en not_active Withdrawn
- 2003-07-16 CA CA2492775A patent/CA2492775C/en not_active Expired - Fee Related
- 2003-07-16 KR KR1020057001328A patent/KR100608415B1/ko not_active Expired - Fee Related
- 2003-07-16 RU RU2005105580/04A patent/RU2318004C2/ru not_active IP Right Cessation
- 2003-07-16 PL PL03375265A patent/PL375265A1/xx unknown
- 2003-07-22 AR AR20030102624A patent/AR040654A1/es not_active Application Discontinuation
- 2003-07-22 US US10/625,033 patent/US7193031B2/en not_active Expired - Fee Related
-
2006
- 2006-03-22 US US11/386,876 patent/US7504477B2/en not_active Expired - Fee Related
-
2008
- 2008-07-14 JP JP2008182692A patent/JP5112203B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2492775A1 (en) | 2004-02-12 |
| KR20050025663A (ko) | 2005-03-14 |
| RU2005105580A (ru) | 2006-01-20 |
| CA2492775C (en) | 2011-06-21 |
| JP5112203B2 (ja) | 2013-01-09 |
| JP4451308B2 (ja) | 2010-04-14 |
| PL375265A1 (en) | 2005-11-28 |
| JP2006502250A (ja) | 2006-01-19 |
| CN1671422A (zh) | 2005-09-21 |
| US7193031B2 (en) | 2007-03-20 |
| KR100608415B1 (ko) | 2006-08-02 |
| CN100337689C (zh) | 2007-09-19 |
| AR040654A1 (es) | 2005-04-13 |
| RU2318004C2 (ru) | 2008-02-27 |
| EP1526872A1 (en) | 2005-05-04 |
| AU2003258518B2 (en) | 2007-01-18 |
| US20040106747A1 (en) | 2004-06-03 |
| US7504477B2 (en) | 2009-03-17 |
| US20060167218A1 (en) | 2006-07-27 |
| MXPA05000796A (es) | 2005-04-19 |
| JP2009062516A (ja) | 2009-03-26 |
| WO2004012773A1 (en) | 2004-02-12 |
| AU2003258518A1 (en) | 2004-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0313212A (pt) | Aditivos de ácido de polialquileno glicol | |
| DE69329903D1 (de) | Bioabbaubare polymere zur zelltransplantation | |
| BRPI0516572A (pt) | métodos e composições para melhorar a produção de proteìnas recombinantes | |
| PT93966A (pt) | Novo sistema de libertacao de anticorpos para modificadores de resposta biologica | |
| BRPI0417916A (pt) | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada | |
| EA200001111A1 (ru) | КОНЪЮГАТЫ ПОЛИОЛ-β-ИНТЕРФЕРОН | |
| FI905956A0 (fi) | Foerfarande foer producering av ett biologiskt aktivt protein. | |
| CA2445577A1 (en) | Subcellular targeting of therapeutic proteins | |
| DE69637229D1 (de) | Lipidisierung hydrophiler Moleküle | |
| DK66391A (da) | Terapeutisk virksomme peptider | |
| CA2434009A1 (en) | Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy | |
| BRPI0616712B8 (pt) | método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas | |
| BR0112925A (pt) | Peptìdeos apresentados por células | |
| BR9911270A (pt) | Métodos e meios para expressão de polipeptìdeos de mamìferos em plantas monocotiledÈneas | |
| BRPI0410562A (pt) | molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo | |
| PT1079849E (pt) | Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica | |
| NO20033441L (no) | Polymerkonjugater av neubastin samt anvendelse derav | |
| Dodt et al. | Mass-encoded reporters reporting proteolytic activity from within the extracellular matrix | |
| ES2113878T3 (es) | Proteina c hibrida. | |
| BRPI0416434A (pt) | métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielina | |
| AU580350B2 (en) | Process for synthesising peptides | |
| WO2004011595A3 (fr) | Vecteurs destines au transfert de molecules d'interet dans des cellules cibles | |
| AR004093A1 (es) | El uso de una proteina derivada de una quimioquina de mamifero y un medicamento util para movilizar celulas tronco hematopoyeticas. | |
| WO2006028561A3 (en) | Novel purified fabi polypeptides from fransicella tularensis | |
| SV2004001457A (es) | "sales estables del acido o-acetilsaliciclico con aminoacidos basicos ii" lea 35839-sv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 47/48; C08G 65/332; C08G 65/337; C08G 65/329. Ipc: C08G 65/337 (2006.01), A61K 47/60 (2017.01), C08G Ipc: C08G 65/337 (2006.01), A61K 47/60 (2017.01), C08G |